CD47 and neoplasm: There is evidence that TAMs express PD-1, have increased PD-1 expression over time and with higher disease stage, and have a decreased ability to phagocytose PD-L1-expressing tumor cells[55], lending a rational approach to combination blockade of PD-L1 and CD47[52].